Exploratory Comparison of the Effects of Cynomorium coccineum L. Methanolic and Aqueous Extracts on Serum Cytokines and Immunoreactive Cyclooxygenase Levels in LPS-Challenged Mice
Department of medical laboratory sciences, Mu’tah University, Karak Jordan.
Corresponding Author E-mail: majali201181@yahoo.com
Download this article as:
ABSTRACT:Gram-negative endotoxemia drives cytokine and eicosanoid-pathway activation that overwhelms endogenous counter-regulation, and in vivo evidence on the effects of Cynomorium coccineum L., and on how the extraction solvent influences them, is limited. This exploratory study compared methanolic and aqueous extracts of the plant in lipopolysaccharide (LPS)-challenged BALB/c mice. Intraperitoneal LD50 values (Reed–Muench method, 24 h observation) were 200 mg/kg for the methanolic and 220 mg/kg for the aqueous extract. Female mice (six per group) received LPS (2.5 mg/kg, i.p.) and, 24 h later, either extract at 10, 20, 40 or 100 mg/kg i.p.; unchallenged, untreated-LPS and ascorbic acid (500 mg/kg) groups served as comparators. Serum IL-6, TNF-α, IL-1β, IL-10 and immunoreactive COX-1 and COX-2 protein were measured by ELISA at a single time point, 48 h after LPS. Each value is the mean ± SD of technical replicates (triplicate wells), so no statistical inference about animals was made. LPS raised IL-6, TNF-α, IL-1β, COX-1 and COX-2 to 320.82, 355.20, 552.81, 160.80 and 260.66 pg/mL. Both extracts lowered these mediators with different profiles: values for IL-6, IL-1β, COX-1 and COX-2 were lower with the methanolic extract, whereas the aqueous extract gave lower TNF-α and higher IL-10. COX-1 and COX-2 were measured as circulating immunoreactive protein and do not demonstrate cyclooxygenase inhibition. The extracts were not chemically characterised. These observations are hypothesis-generating and need confirmation with per-animal measurements, chemical standardisation and a time-course.
KEYWORDS:Cyclooxygenase; Cynomorium coccineum; Cytokines; Extraction solvent; Lipopolysaccharide
Introduction
Systemic inflammation is a coordinated defence response to pathogens, tissue injury and microbial endotoxins, but uncontrolled activation leads to tissue damage, shock and multi-organ failure.1,2 Lipopolysaccharide (LPS), a component of the Gram-negative outer membrane, activates innate immunity through the Toll-like receptor 4 (TLR4) complex and the nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways,3,4 driving the release of tumour necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and interleukin-1 beta (IL-1β)1,5,6 and the induction of cyclooxygenase-1 and -2 (COX-1, COX-2), which generate prostanoids.7,8 The anti-inflammatory cytokine interleukin-10 (IL-10) provides counter-regulation,9,10 but in endotoxemic shock this feedback is often overwhelmed.1,2 Corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) are limited by adverse effects,7,8 which sustains interest in natural products that act at several inflammatory nodes.4,11
Plant secondary metabolites can act at several of these points: polyphenols and flavonoids dampen TLR4/NF-κB signalling,4,11,12 triterpenic acids modulate the NF-κB, Nrf2 and JAK/STAT3 axes,13 and many natural products interfere with NLRP3 inflammasome activation,14,15 whereas polysaccharides act mainly at macrophage pattern-recognition receptors and can steer cytokine output towards a regulatory phenotype.16
Cynomorium coccineum L. (Cynomoriaceae), the “Maltese mushroom”, is an obligate, non-photosynthetic holoparasite found across the Mediterranean Basin, North Africa, the Arabian Peninsula and western Asia.17 In regional folk medicine it has been used as a tonic and against bleeding, dysentery, poor wound healing and reproductive complaints.17 Reported constituents include gallic acid and its derivatives, cyanidin 3-O-glucoside and related anthocyanins, condensed and polymeric polyphenols, sterols, betaine, organic acids and an oil rich in essential fatty acids.17-20 Extracts show antioxidant capacity in many chemical and biological assays, distributed differently between aqueous and organic fractions18,20; antimicrobial, antifungal, anti-tyrosinase and antiproliferative activities have also been documented in vitro, and antitumour activity in vivo.17,21,22 The extraction solvent has repeatedly been found to determine both the phytochemical profile obtained from C. coccineum and the resulting bioactivity,18,20 as it does in medicinal plants generally.16,23
Even so, the anti-inflammatory pharmacology of C. coccineum remains poorly explored, and we know of no in vivo study of how the extraction solvent shapes cytokine profiles and cyclooxygenase levels after LPS challenge. This exploratory study therefore compared methanolic and aqueous C. coccineum extracts in LPS-challenged mice, measuring serum TNF-α, IL-6, IL-1β, IL-10 and circulating immunoreactive COX-1 and COX-2 protein. The extracts were given 24 h after LPS, so the design tests a therapeutic rather than a prophylactic paradigm.
Materials and Methods
Plant Material Collection and Identification
Cynomorium coccineum was collected in March–April 2022 at Lajjun, Karak, in southern Jordan. Dr. Feryal Al-Khresat (Department of Biology, Mutah University, Karak, Jordan) identified the plant, and a voucher specimen (MU2022-03) was deposited in that department.
Extract Preparation
The plant was washed, air-dried and coarsely ground. The whole aerial spadix was used because anthocyanins in this species are concentrated in the red outer layer, and composition differs considerably between the whole spadix, the peeled inner tissue and the aerial part.17,18 The powder was macerated separately in absolute methanol and in distilled water (1:10 w/v) for 24 h at room temperature (25 ± 2 °C) with occasional manual shaking. After filtration to remove plant residue, the solvents were evaporated under reduced pressure in a rotary evaporator at 40 °C, and the crude extracts were kept at 4 °C until use. Doses refer to the mass of crude extract.
Animals
Female BALB/c mice (6–8 weeks old, 22–28 g) were obtained from the animal house of Applied Science University, Amman, Jordan. They were housed six per polypropylene cage at 22 ± 2 °C and 50 ± 10% relative humidity under a 12 h light/dark cycle, with free access to water and standard rodent chow, and were acclimatised for 7 days before the experiment. Mice were fasted overnight (12 h), with water available, before intraperitoneal dosing. Only females were used, to limit inter-animal variability in the inflammatory response.
All procedures complied with the NIH Guide for the Care and Use of Laboratory Animals (8th edition)24 and EU Directive 2010/63/EU25 and were approved by the Research Ethics Committee of the Faculty of Allied Medical Sciences (FAMS) (approval no. 013/01/2026, 7 January 2026). The experiments were carried out at Mutah University between February and April 2026. The study is reported in line with the ARRIVE 2.0 guidelines.26
Animals were assigned to groups using a computer-generated random number sequence, and the investigators who ran the ELISA assays were blinded to allocation. No formal sample-size calculation was done; group sizes followed those typical of comparable exploratory studies with this model. No animal and no data point (outliers included) was excluded from analysis.
Acute Intraperitoneal Toxicity Study
Acute toxicity was determined after intraperitoneal injection. Groups of BALB/c mice (n = 10 per dose) received graded doses of each extract (50, 100, 150, 200, 250 and 300 mg/kg, i.p.) and were monitored for abnormal clinical signs for 24 h. Survival (surviving mice / total mice × 100%) was recorded for each group, and the median lethal dose was derived by the Reed–Muench method.27 Observation was limited to 24 h. Acute toxicity testing of other plant extracts in mice has been reported.28,29
Study Design
Mice were randomly assigned to seven groups, and the protocol was run in parallel for the methanolic and aqueous extracts:
- Group 1 (Normal/Sham): distilled water only.
- Group 2 (model/negative control): LPS (2.5 mg/kg, i.p.), then vehicle 24 h later.
- Group 3: LPS (2.5 mg/kg, i.p.), then coccineum extract at 10 mg/kg i.p. 24 h later.
- Group 4: LPS (2.5 mg/kg, i.p.), then coccineum extract at 20 mg/kg i.p. 24 h later.
- Group 5: LPS (2.5 mg/kg, i.p.), then coccineum extract at 40 mg/kg i.p. 24 h later.
- Group 6: LPS (2.5 mg/kg, i.p.), then coccineum extract at 100 mg/kg i.p. 24 h later.
- Group 7 (reference compound): LPS (2.5 mg/kg, i.p.), then ascorbic acid at 500 mg/kg i.p. 24 h later.
Extracts were suspended in 1% DMSO and injected intraperitoneally at 10 mL/kg; the untreated LPS group received the same volume of vehicle at 24 h. LPS was obtained from ChemCruz (lot B2823).
Each extract was given i.p. as a single dose 24 h after LPS, and blood was collected 24 h later (48 h after LPS).
Ascorbic acid was included as a reference compound because of its documented antioxidant activity and its recognised role in supporting innate immunity and modulating inflammatory responses.30 It is not an established anti-inflammatory comparator in this model, so comparisons with it are descriptive only.
Sample Collection and Biochemical Analysis
Blood (1 mL) was collected by cardiac puncture under isoflurane anaesthesia 24 h after treatment (48 h after LPS) and left to clot at room temperature. After 10 min the samples were centrifuged at 2500 rpm for 10 min, and the serum was transferred to clean tubes and stored at −21 °C for up to 2 weeks until analysis.
Serum IL-6, TNF-α, IL-1β and IL-10, together with immunoreactive COX-1 and COX-2, were quantified with commercial enzyme-linked immunosorbent assay (ELISA) kits (Abcam, Cambridge, MA, USA) following the manufacturer’s instructions.
Statistical Analysis
Results are given as mean ± standard deviation of technical replicates (triplicate ELISA wells). The SD therefore reflects the precision of the assay and not the variability between animals. Six mice were studied per group.
Because replicate wells are not independent observations, no significance tests were applied and no p values are reported for the ELISA data. Group differences are described from the mean values, as fold changes over the normal baseline, and as the percentage reversal of the LPS-induced increase (Table 7). Means and SDs were calculated in GraphPad Prism v.9.5.
Results
Acute Intraperitoneal Toxicity and Dose Selection
The intraperitoneal LD50 was 200 mg/kg for the methanolic extract and 220 mg/kg for the aqueous extract. The efficacy study used intraperitoneal doses of 10, 20, 40 and 100 mg/kg; no lethality or abnormal clinical signs occurred at any of these doses during the experiment (n = 6 per group). Because mice were observed for 24 h only, these LD50 values are provisional.
Effect of C. coccineum Extracts on Serum IL-6
LPS (2.5 mg/kg) raised serum IL-6 about 4.4-fold, from 72.66 pg/mL in normal mice to 320.82 pg/mL in untreated model animals, in keeping with the amplifying role attributed to IL-6 in the acute phase of endotoxemia.6
Both extracts lowered serum IL-6 relative to the LPS group (Table 1). With the methanolic extract the fall was progressive and dose-related, from 256.04 pg/mL at 10 mg/kg to 47.23 pg/mL at 100 mg/kg. The 100 mg/kg value lay below both the unchallenged controls (72.66 pg/mL) and the ascorbic acid group (500 mg/kg; 81.82 pg/mL), which equals a 110.2% reversal of the LPS-induced rise, that is, an overshoot past full normalisation.
The aqueous extract also lowered IL-6 (173.72 pg/mL at 100 mg/kg; Table 1), but its dose–response was not monotonic: the 20 mg/kg value (299.07 pg/mL) was higher than the 10 mg/kg value (267.40 pg/mL), so a dose-dependent effect is not claimed for this extract. At every matched dose the methanolic extract gave lower IL-6 than the aqueous extract.
Table 1: Serum IL-6 in LPS-challenged mice after treatment with methanolic or aqueous C. coccineum extract (mean ± SD of technical replicates).
|
Experimental group |
Dose (mg/kg) | Methanolic extract (pg/mL) | Aqueous extract (pg/mL) |
| Normal control | — | 72.66 ± 2.00 |
72.66 ± 2.00 |
|
LPS model |
2.5 | 320.82 ± 2.40 | 320.82 ± 2.40 |
| Extract group 1 | 10 | 256.04 ± 1.20 |
267.40 ± 3.50 |
|
Extract group 2 |
20 | 209.49 ± 2.10 | 299.07 ± 4.70 |
| Extract group 3 | 40 | 154.15 ± 1.90 |
196.90 ± 1.40 |
|
Extract group 4 |
100 | 47.23 ± 1.30 | 173.72 ± 0.60 |
| Reference compound (AA) | 500 | 81.82 ± 1.40 |
81.82 ± 1.40 |
Mean ± SD of technical replicates (triplicate ELISA wells); the SD reflects assay precision, not variability between animals, and no significance tests were applied. In the LPS model row the dose column gives the LPS dose; in the other rows it gives the extract or ascorbic acid dose.
Effect of C. coccineum Extracts on Serum TNF-α
LPS increased serum TNF-α roughly eighteen-fold (355.20 versus 19.33 pg/mL in normal controls).
Both extracts lowered TNF-α relative to the untreated LPS group in a dose-related fashion (Table 2). With the methanolic extract, concentrations fell from 256.95 pg/mL at 10 mg/kg to 82.69 pg/mL at 100 mg/kg, which was close to the ascorbic acid group (500 mg/kg; 79.77 pg/mL); no claim of equivalence is made.
The aqueous extract gave lower TNF-α than the methanolic extract at every matched dose, with 182.35 pg/mL at 10 mg/kg and 43.16 pg/mL at 100 mg/kg. At 40 and 100 mg/kg the aqueous values (71.81 and 43.16 pg/mL) were lower than that of the ascorbic acid group (79.77 pg/mL). This is not a like-for-like potency comparison, however, because the doses differ widely (40–100 versus 500 mg/kg) and the compounds belong to different classes.
Table 2: Serum TNF-α in LPS-challenged mice after treatment with methanolic or aqueous C. coccineum extract (mean ± SD of technical replicates).
|
Experimental group |
Dose (mg/kg) | Methanolic extract (pg/mL) | Aqueous extract (pg/mL) |
| Normal control | — | 19.33 ± 0.10 |
19.33 ± 0.10 |
|
LPS model |
2.5 | 355.20 ± 1.19 | 355.20 ± 1.19 |
| Extract group 1 | 10 | 256.95 ± 3.42 |
182.35 ± 2.03 |
|
Extract group 2 |
20 | 141.75 ± 2.37 | 97.55 ± 2.32 |
| Extract group 3 | 40 | 100.23 ± 0.87 |
71.81 ± 1.58 |
|
Extract group 4 |
100 | 82.69 ± 0.83 | 43.16 ± 0.80 |
| Reference compound (AA) | 500 | 79.77 ± 1.90 |
79.77 ± 1.90 |
Mean ± SD of technical replicates (triplicate ELISA wells); the SD reflects assay precision, not variability between animals, and no significance tests were applied. In the LPS model row the dose column gives the LPS dose; in the other rows it gives the extract or ascorbic acid dose.
Effect of C. coccineum Extracts on Serum Immunoreactive COX-1
LPS raised serum immunoreactive COX-1 from 50.49 pg/mL in normal controls to 160.80 pg/mL in untreated model mice.
Both extracts reduced COX-1 dose-dependently relative to the LPS group (Table 3). Methanolic values declined from 128.46 pg/mL at 10 mg/kg to 82.37 pg/mL at 100 mg/kg, and aqueous values from 148.65 to 92.36 pg/mL over the same range.
At all matched doses, COX-1 was lower with the methanolic than with the aqueous extract. Neither extract reached the level of the ascorbic acid group (500 mg/kg; 60.59 pg/mL). The methanolic extract at 100 mg/kg reversed about 71% of the LPS-induced rise above normal, and COX-1 did not fall below the normal control level in any group.
Table 3: Serum immunoreactive COX-1 in LPS-challenged mice after treatment with methanolic or aqueous C. coccineum extract (mean ± SD of technical replicates).
|
Experimental group |
Dose (mg/kg) | Methanolic extract (pg/mL) | Aqueous extract (pg/mL) |
| Normal control | — | 50.49 ± 0.06 |
50.49 ± 0.06 |
|
LPS model |
2.5 | 160.80 ± 1.02 | 160.80 ± 1.02 |
| Extract group 1 | 10 | 128.46 ± 0.15 |
148.65 ± 1.87 |
|
Extract group 2 |
20 | 109.99 ± 2.20 | 139.98 ± 0.68 |
| Extract group 3 | 40 | 94.95 ± 0.82 |
102.76 ± 0.26 |
|
Extract group 4 |
100 | 82.37 ± 0.15 | 92.36 ± 0.60 |
| Reference compound (AA) | 500 | 60.59 ± 1.22 |
60.59 ± 1.22 |
Mean ± SD of technical replicates (triplicate ELISA wells); the SD reflects assay precision, not variability between animals, and no significance tests were applied. In the LPS model row the dose column gives the LPS dose; in the other rows it gives the extract or ascorbic acid dose.
Effect of C. coccineum Extracts on Serum Immunoreactive COX-2
LPS approximately tripled serum immunoreactive COX-2, from 90.14 pg/mL in normal controls to 260.66 pg/mL.
Both extracts lowered COX-2 relative to the untreated LPS group in a dose-related way (Table 4): from 240.58 to 150.23 pg/mL across 10–100 mg/kg for the methanolic extract, and from 250.36 to 183.16 pg/mL for the aqueous extract.
The methanolic extract gave lower COX-2 values than the aqueous extract at every matched dose. At 100 mg/kg the methanolic value (150.23 pg/mL) remained above that of the ascorbic acid group (500 mg/kg; 140.00 pg/mL) and corresponded to a reduction of roughly 65% of the LPS-induced increase in circulating immunoreactive COX-2.
Table 4: Serum immunoreactive COX-2 in LPS-challenged mice after treatment with methanolic or aqueous C. coccineum extract (mean ± SD of technical replicates).
|
Experimental group |
Dose (mg/kg) | Methanolic extract (pg/mL) | Aqueous extract (pg/mL) |
| Normal control | — | 90.14 ± 0.11 |
90.14 ± 0.11 |
|
LPS model |
2.5 | 260.66 ± 0.86 | 260.66 ± 0.86 |
| Extract group 1 | 10 | 240.58 ± 0.70 |
250.36 ± 0.67 |
|
Extract group 2 |
20 | 220.56 ± 0.26 | 236.80 ± 2.15 |
| Extract group 3 | 40 | 190.20 ± 0.67 |
203.25 ± 0.32 |
|
Extract group 4 |
100 | 150.23 ± 2.49 | 183.16 ± 0.44 |
| Reference compound (AA) | 500 | 140.00 ± 0.19 |
140.00 ± 0.19 |
Mean ± SD of technical replicates (triplicate ELISA wells); the SD reflects assay precision, not variability between animals, and no significance tests were applied. In the LPS model row the dose column gives the LPS dose; in the other rows it gives the extract or ascorbic acid dose.
Effect of C. coccineum Extracts on Serum IL-1β
LPS raised serum IL-1β by more than fifty-fold, from 10.40 pg/mL in normal animals to 552.81 pg/mL.
Both extracts reduced IL-1β relative to the untreated LPS group in a dose-related manner (Table 5). The methanolic extract lowered it from 332.15 pg/mL at 10 mg/kg to 234.66 pg/mL at 100 mg/kg, whereas the aqueous extract moved it from 542.36 to 284.37 pg/mL, with minimal effect at 10 mg/kg.
At all matched doses the methanolic extract produced lower IL-1β than the aqueous extract. Neither extract reached the level of the ascorbic acid group (500 mg/kg; 180.48 pg/mL). At 100 mg/kg, the methanolic extract reversed about 58% of the LPS-induced increase.
Table 5: Serum IL-1β in LPS-challenged mice after treatment with methanolic or aqueous C. coccineum extract (mean ± SD of technical replicates).
|
Experimental group |
Dose (mg/kg) | Methanolic extract (pg/mL) | Aqueous extract (pg/mL) |
| Normal control | — | 10.40 ± 4.02 |
10.40 ± 4.02 |
|
LPS model |
2.5 | 552.81 ± 1.36 | 552.81 ± 1.36 |
| Extract group 1 | 10 | 332.15 ± 0.87 |
542.36 ± 1.14 |
|
Extract group 2 |
20 | 312.45 ± 0.87 | 380.46 ± 0.80 |
| Extract group 3 | 40 | 245.26 ± 3.06 |
332.16 ± 1.17 |
|
Extract group 4 |
100 | 234.66 ± 2.00 | 284.37 ± 1.68 |
| Reference compound (AA) | 500 | 180.48 ± 0.31 |
180.48 ± 0.31 |
Mean ± SD of technical replicates (triplicate ELISA wells); the SD reflects assay precision, not variability between animals, and no significance tests were applied. In the LPS model row the dose column gives the LPS dose; in the other rows it gives the extract or ascorbic acid dose.
Effect of C. coccineum Extracts on Serum IL-10
LPS raised serum IL-10 about 7.3-fold, from 15.30 pg/mL in normal controls to 112.27 pg/mL, consistent with the endogenous counter-regulatory response described in acute endotoxemia.9
Both extracts raised IL-10 above the LPS-only level (Table 6). The methanolic extract did so progressively, from 128.73 pg/mL at 10 mg/kg to 192.69 pg/mL at 100 mg/kg, while the aqueous extract rose from 144.67 pg/mL at 10 mg/kg to 216.41 pg/mL at 40 mg/kg and 215.36 pg/mL at 100 mg/kg.
IL-10 was higher with the aqueous than with the methanolic extract at all four doses. The aqueous response plateaued at 40 mg/kg, with no further rise at 100 mg/kg, and the maximum was similar in magnitude to that of the ascorbic acid group (500 mg/kg; 209.15 pg/mL).
Table 6: Serum IL-10 in LPS-challenged mice after treatment with methanolic or aqueous C. coccineum extract (mean ± SD of technical replicates).
|
Experimental group |
Dose (mg/kg) | Methanolic extract (pg/mL) | Aqueous extract (pg/mL) |
| Normal control | — | 15.30 ± 0.70 |
15.30 ± 0.70 |
|
LPS model |
2.5 | 112.27 ± 1.15 | 112.27 ± 1.15 |
| Extract group 1 | 10 | 128.73 ± 0.41 |
144.67 ± 1.18 |
|
Extract group 2 |
20 | 147.89 ± 2.44 | 158.15 ± 0.83 |
| Extract group 3 | 40 | 170.74 ± 4.45 |
216.41 ± 1.22 |
|
Extract group 4 |
100 | 192.69 ± 4.80 | 215.36 ± 1.74 |
| Reference compound (AA) | 500 | 209.15 ± 4.20 |
209.15 ± 4.20 |
Mean ± SD of technical replicates (triplicate ELISA wells); the SD reflects assay precision, not variability between animals, and no significance tests were applied. In the LPS model row the dose column gives the LPS dose; in the other rows it gives the extract or ascorbic acid dose.
Summary of Effect Magnitude Across Mediators
To compare treatments across mediators measured on different scales, each effect was expressed as the percentage reversal of the LPS-induced increase over the normal baseline, calculated as (LPS − treated) / (LPS − normal) × 100. Values above 100% mean that the treated concentration fell below the unchallenged baseline; negative values for IL-10 denote a further rise above the LPS level, which is the desired direction for this regulatory cytokine.
Table 7: Percentage reversal of the LPS-induced change in each mediator, by extract and dose (calculated from the group means in Tables 1–6).
|
Mediator |
LPS fold-change | Dose (mg/kg) | Methanolic (%) | Aqueous (%) | AA 500 mg/kg (%) |
| IL-6 | 4.42 | 10 | 26.1 |
21.5 |
96.3 |
|
20 |
44.9 | 8.8 | |||
| 40 | 67.2 |
49.9 |
|||
|
100 |
110.2 |
59.3 |
|||
|
TNF-α |
18.38 | 10 | 29.3 | 51.5 | 82.0 |
| 20 | 63.6 |
76.7 |
|||
|
40 |
75.9 | 84.4 | |||
| 100 | 81.1 |
92.9 |
|||
|
COX-1 (immunoreactive) |
3.18 |
10 |
29.3 | 11.0 | 90.8 |
| 20 | 46.1 |
18.9 |
|||
|
40 |
59.7 | 52.6 | |||
| 100 | 71.1 |
62.0 |
|||
|
COX-2 (immunoreactive) |
2.89 |
10 |
11.8 | 6.0 | 70.8 |
| 20 | 23.5 |
14.0 |
|||
|
40 |
41.3 | 33.7 | |||
| 100 | 64.8 |
45.4 |
|||
|
IL-1β |
53.15 |
10 |
40.7 | 1.9 | 68.6 |
| 20 | 44.3 |
31.8 |
|||
|
40 |
56.7 | 40.7 | |||
| 100 | 58.7 |
49.5 |
|||
|
IL-10 |
7.34 |
10 |
−17.0 | −33.4 | −99.9 |
| 20 | −36.7 |
−47.3 |
|||
|
40 |
−60.3 | −107.4 | |||
| 100 | −82.9 |
−106.3 |
Three features stand out in this summary. First, the methanolic advantage over the aqueous extract is greatest for IL-1β at low dose (40.7% versus 1.9% at 10 mg/kg) and for IL-6 at high dose (110.2% versus 59.3% at 100 mg/kg). Second, the aqueous advantage for TNF-α holds at every dose and is proportionally largest at 10 mg/kg (51.5% versus 29.3%). Third, at 40 mg/kg the aqueous extract exceeded full reversal for IL-10 (−107.4%), meaning that IL-10 rose further above the LPS level than the endotoxin challenge itself had lifted it above baseline.
Discussion
In this exploratory study, LPS produced a marked rise in serum TNF-α, IL-6, IL-1β and immunoreactive COX-1 and COX-2 protein 48 h after challenge, with a smaller rise in IL-10. Both extracts, given 24 h after LPS, were associated with lower pro-inflammatory values and higher IL-10, with different profiles for the two solvents: the methanolic extract gave lower IL-6, IL-1β, COX-1 and COX-2 at every matched dose, whereas the aqueous extract gave lower TNF-α and higher IL-10 (Tables 1–7). The SDs reported are those of technical replicates, so these are descriptive differences between group means that have not been tested statistically; they need confirmation with per-animal measurements.
One explanation for the divergence is that each solvent recovers different constituents, as comparative work on this species and on other medicinal plants suggests.18,20,23 Aqueous and methanolic extracts of C. coccineum differ in phenolic and flavonoid content and antioxidant behaviour,18 water efficiently recovers polar polyphenols and anthocyanins17,20,31 and polysaccharides, whose activity varies with extraction method,16 and anthocyanins and related polyphenols have been linked to modulation of inflammatory signalling in vivo.31-33 This remains an assumption, because neither extract was chemically characterised. Dose equivalence is a second caveat: both extracts were dosed at matched mass of crude extract (mg/kg), but yields are likely to differ between solvents and the two extracts have different LD50 values (200 versus 220 mg/kg), so matched mass does not imply matched exposure to active constituents. Without yields, standardisation to marker compounds or chemical profiling, the solvent effect can be described but not explained.
COX-1 and COX-2 were measured as circulating immunoreactive protein. Because both enzymes are membrane-bound and not secreted, serum levels cannot indicate prostanoid-synthesising activity and most plausibly reflect release from activated or damaged cells. The results therefore show lower circulating levels of a marker of cyclooxygenase-expressing cell activation, not inhibition of cyclooxygenase activity.
With the methanolic extract at 100 mg/kg, IL-6 fell below the value in unchallenged animals (a 110.2% reversal; Table 7). A value below physiological baseline calls for caution rather than being read as greater efficacy: IL-6 contributes to host defence,1,6 and 100 mg/kg is about half of the LD50, so incipient immunosuppression or subclinical toxicity cannot be excluded from these data.
TNF-α initiates the inflammatory cascade and stimulates secondary cytokines, including IL-6 and IL-1β.34 The aqueous extract gave the lowest TNF-α together with the highest IL-10 values; because IL-10 represses TNF-α synthesis through STAT3 and SOCS3,9,10 this reciprocal pattern is compatible with, but does not demonstrate, a mechanism in which lower TNF-α follows higher IL-10. The larger falls in IL-6, IL-1β and COX levels with the methanolic extract could reflect effects on NF-κB-dependent signalling4,5,11-13 or, for IL-1β, on NLRP3 inflammasome activation;12,14,15 neither was assessed here, and both remain hypotheses.
Blood was collected 48 h after LPS, well after the classical TNF-α (1–2 h) and IL-6 (2–6 h) peaks in murine LPS models,35,36 so the model is better described as LPS-challenged mice than as acute endotoxemia. The sustained 18-fold TNF-α and 53-fold IL-1β elevations at this time are later than the classical profile. Possible contributors include the relatively high LPS dose (2.5 mg/kg), secondary waves of mediator release, and strain- and sex-specific differences in BALB/c females, but these explanations are speculative. With a single time point and no time-course, the possibility that the model behaved atypically, or that the assays read something other than bioactive cytokine, cannot be set aside, and every comparison here depends on it.
The extracts were given 24 h after LPS, so the design tests treatment of an established inflammatory response rather than prevention. Other plant extracts have been reported to limit LPS-driven inflammation in mice through macrophage reprogramming37 or, for isolated polymethoxyflavones, attenuation of inflammatory responses;38 whether similar mechanisms apply to C. coccineum is not known.
Limitations
This study has several limitations. First, the SDs reported are those of technical replicates (triplicate wells) and not of individual animals, so no inferential statistics could be applied; the results are exploratory and descriptive, and need confirmation by per-animal measurements with appropriate statistics. Second, blood was collected at a single time point (48 h after LPS) with no time-course, so the kinetics of the response, including the unusually late elevation discussed above, could not be examined; body weights and clinical scores are not reported. Third, COX-1 and COX-2 were measured as circulating immunoreactive protein only, with no prostanoid or enzyme-activity endpoint, so no inhibition of cyclooxygenase activity can be inferred. Fourth, the extracts were not chemically characterised (no total phenolic or flavonoid content, HPLC or LC-MS) and doses were matched by mass of crude extract rather than by composition, so solvent chemistry cannot be separated from differences in the amount of active material delivered. Fifth, ascorbic acid is not an established anti-inflammatory comparator in this model, and no dexamethasone, indomethacin or selective COX-2 inhibitor was included, so comparisons with it are descriptive. Sixth, acute toxicity was observed for 24 h rather than 14 days and the LD50 estimates are provisional; the 100 mg/kg dose lies at about half of the LD50 of each extract, and IL-6 values below baseline at that dose may reflect excessive suppression rather than greater efficacy. Finally, only female BALB/c mice, a single LPS dose and serum endpoints were studied, without survival, organ-injury or tissue endpoints.
Conclusion
Intraperitoneal administration of Cynomorium coccineum extracts 24 h after LPS challenge lowered circulating inflammatory mediators in BALB/c mice, with differing profiles between the two solvents: values for IL-6, IL-1β and circulating immunoreactive COX-1 and COX-2 were lower with the methanolic extract, whereas TNF-α was lower and IL-10 higher with the aqueous extract. These observations are exploratory: the reported SDs come from technical replicates, no statistical inference was made, and the extracts were not chemically characterised. The COX results reflect immunoreactive protein in serum and do not show inhibition of cyclooxygenase activity, and the findings establish neither a mechanism nor tissue protection. Priorities for future work are per-animal measurements with appropriate statistics, chemical characterisation and standardisation of both extracts, a time-course and a recognised anti-inflammatory comparator, prostanoid and tissue cyclooxygenase measurements, analysis of the NF-κB, NLRP3 and STAT3 pathways, extended toxicity testing, and organ-injury and survival endpoints.
Acknowledgement
The author thanks Dr. Feryal Al-Khresat (Department of Biology, Mutah University) for identifying the plant material, and the animal house of Applied Science University, Amman, for supplying the animals.
Funding Sources
The author received no financial support for the research, authorship, and/or publication of this article.
Conflict of Interest
The author declares no conflict of interest.
Data Availability Statement
The manuscript incorporates all datasets produced or examined throughout this research study. Other data can be requested from the author.
Ethics Statement
All animal procedures were approved by the Research Ethics Committee of the Faculty of Allied Medical Sciences (FAMS) (approval no. 013/01/2026, 7 January 2026) and were conducted in accordance with the NIH Guide for the Care and Use of Laboratory Animals (8th edition) and EU Directive 2010/63/EU.
Informed Consent Statement
This study did not involve human participants, and therefore, informed consent was not required.
Clinical Trial Registration
This research does not involve any clinical trials.
Permission to Reproduce Material from Other Sources
Not applicable.
Author Contributions
The sole author, Ibrahim S. Majali, was responsible for the conceptualization, methodology, data collection, analysis, writing, and final approval of the manuscript.
References
- Jarczak D, Nierhaus A. Cytokine storm—definition, causes, and implications. Int J Mol Sci. 2022;23(19):11740. doi:10.3390/ijms231911740
CrossRef - Nedeva C. Inflammation and cell death of the innate and adaptive immune system during sepsis. Biomolecules. 2021;11(7):1011. doi:10.3390/biom11071011
CrossRef - Cochet F, Peri F. The role of carbohydrates in the lipopolysaccharide (LPS)/Toll-like receptor 4 (TLR4) signalling. Int J Mol Sci. 2017;18(11):2318. doi:10.3390/ijms18112318
CrossRef - Yu C, Wang D, Yang Z, Wang T. Pharmacological effects of polyphenol phytochemicals on the intestinal inflammation via targeting TLR4/NF-κB signaling pathway. Int J Mol Sci. 2022;23(13):6939. doi:10.3390/ijms23136939
CrossRef - Liu D, Zhong Z, Karin M. NF-κB: a double-edged sword controlling inflammation. Biomedicines. 2022;10(6):1250. doi:10.3390/biomedicines10061250
CrossRef - Paranga TG, Mitu I, Pavel-Tanasa M, et al. Cytokine storm in COVID-19: exploring IL-6 signaling and cytokine-microbiome interactions as emerging therapeutic approaches. Int J Mol Sci. 2024;25(21):11411. doi:10.3390/ijms252111411
CrossRef - Jara-Gutiérrez Á, Baladrón V. The role of prostaglandins in different types of cancer. Cells. 2021;10(6):1487. doi:10.3390/cells10061487
CrossRef - Kolawole OR, Kashfi K. NSAIDs and cancer resolution: new paradigms beyond cyclooxygenase. Int J Mol Sci. 2022;23(3):1432. doi:10.3390/ijms23031432
CrossRef - Martinez-Espinosa I, Serrato JA, Ortiz-Quintero B. Role of IL-10-producing natural killer cells in the regulatory mechanisms of inflammation during systemic infection. Biomolecules. 2022;12(1):4. doi:10.3390/biom12010004
CrossRef - Nagata K, Nishiyama C. IL-10 in mast cell-mediated immune responses: anti-inflammatory and proinflammatory roles. Int J Mol Sci. 2021;22(9):4972. doi:10.3390/ijms22094972
CrossRef - Al-Khayri JM, Sahana GR, Nagella P, Joseph BV, Alessa FM, Al-Mssallem MQ. Flavonoids as potential anti-inflammatory molecules: a review. Molecules. 2022;27(9):2901. doi:10.3390/molecules27092901
CrossRef - Kariagina A, Doseff AI. Anti-inflammatory mechanisms of dietary flavones: tapping into nature to control chronic inflammation in obesity and cancer. Int J Mol Sci. 2022;23(24):15753. doi:10.3390/ijms232415753
CrossRef - Mioc M, Milan A, Malița D, et al. Recent advances regarding the molecular mechanisms of triterpenic acids: a review (part I). Int J Mol Sci. 2022;23(14):7740. doi:10.3390/ijms23147740
CrossRef - Liu B, Yu J. Anti-NLRP3 inflammasome natural compounds: an update. Biomedicines. 2021;9(2):136. doi:10.3390/biomedicines9020136
CrossRef - El-Sayed S, Freeman S, Bryce RA. A selective review and virtual screening analysis of natural product inhibitors of the NLRP3 inflammasome. Molecules. 2022;27(19):6213. doi:10.3390/molecules27196213
CrossRef - Xiao W, Zhou P, Wang X, Zhao R, Wang Y. Comparative characterization and immunomodulatory activities of polysaccharides extracted from the radix of Platycodon grandiflorum with different extraction methods. Molecules. 2022;27(15):4759. doi:10.3390/molecules27154759
CrossRef - Zucca P, Bellot S, Rescigno A. The modern use of an ancient plant: exploring the antioxidant and nutraceutical potential of the Maltese mushroom (Cynomorium coccineum). Antioxidants (Basel). 2019;8(8):289. doi:10.3390/antiox8080289
CrossRef - Zucca P, Rosa A, Tuberoso CIG, et al. Evaluation of antioxidant potential of “Maltese mushroom” (Cynomorium coccineum) by means of multiple chemical and biological assays. Nutrients. 2013;5(1):149-161. doi:10.3390/nu5010149
CrossRef - Rosa A, Nieddu M, Piras A, Atzeri A, Putzu D, Rescigno A. Maltese mushroom (Cynomorium coccineum) as source of oil with potential anticancer activity. Nutrients. 2015;7(2):849-864. doi:10.3390/nu7020849
CrossRef - Ben Attia I, Zucca P, Marincola FC, et al. Chemical composition and antioxidant potential differences between Cynomorium coccineum growing in Italy and in Tunisia: effect of environmental stress. Diversity. 2018;10(3):53. doi:10.3390/d10030053
CrossRef - Sdiri M, Li X, Du W, et al. Anticancer activity of Cynomorium coccineum. Cancers (Basel). 2018;10(10):354. doi:10.3390/cancers10100354
CrossRef - Griffin S, Alkhayer R, Mirzoyan S, et al. Nanosizing Cynomorium: thumbs up for potential antifungal applications. Inventions. 2017;2(3):24. doi:10.3390/inventions2030024
CrossRef - Baig MW, Ahmed M, Akhtar N, et al. Caralluma tuberculataE.Br manifests extraction medium reliant disparity in phytochemical and pharmacological analysis. Molecules. 2021;26(24):7530. doi:10.3390/molecules26247530
CrossRef - National Research Council. Guide for the Care and Use of Laboratory Animals. 8th ed. National Academies Press; 2011. doi:10.17226/12910
CrossRef - European Parliament, Council of the European Union. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Off J Eur Union. 2010;L276:33-79. http://data.europa.eu/eli/dir/2010/63/oj
- Percie du Sert N, Hurst V, Ahluwalia A, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. doi:10.1371/journal.pbio.3000410
CrossRef - Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Epidemiol. 1938;27(3):493-497. doi:10.1093/oxfordjournals.aje.a118408
CrossRef - Alruwad MI, Salah El Dine R, Gendy AM, et al. Insights into Clematis cirrhosa ethanol extract: cytotoxic effects, LC-ESI-QTOF-MS/MS chemical profiling, molecular docking, and acute toxicity study. Pharmaceuticals (Basel). 2024;17(10):1347. doi:10.3390/ph17101347
CrossRef - Hu G, Qi Z, Wang A, Jia J. Effects of deacidification on composition of Schisandra chinensis ethanolic extract and studies on acute toxicity in mice. Molecules. 2020;25(24):6038. doi:10.3390/molecules25246038
CrossRef - Carr AC, Maggini S. Vitamin C and immune function. Nutrients. 2017;9(11):1211. doi:10.3390/nu9111211
CrossRef - Mattioli R, Francioso A, Mosca L, Silva P. Anthocyanins: a comprehensive review of their chemical properties and health effects on cardiovascular and neurodegenerative diseases. Molecules. 2020;25(17):3809. doi:10.3390/molecules25173809
CrossRef - Correia P, Araújo P, Ribeiro C, et al. Anthocyanin-related pigments: natural allies for skin health maintenance and protection. Antioxidants (Basel). 2021;10(7):1038. doi:10.3390/antiox10071038
CrossRef - Blesso CN. Dietary anthocyanins and human health. Nutrients. 2019;11(9):2107. doi:10.3390/nu11092107
CrossRef - Jang DI, Lee AH, Shin HY, et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int J Mol Sci. 2021;22(5):2719. doi:10.3390/ijms22052719
CrossRef - Copeland S, Warren HS, Lowry SF, Calvano SE, Remick D. Acute inflammatory response to endotoxin in mice and humans. Clin Diagn Lab Immunol. 2005;12(1):60-67. doi:10.1128/CDLI.12.1.60-67.2005
CrossRef - Remick DG, Newcomb DE, Bolgos GL, Call DR. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock. 2000;13(2):110-116. doi:10.1097/00024382-200013020-00004
CrossRef - Wu H, Guo M, Zhao L, et al. Siraitia grosvenorii extract protects lipopolysaccharide-induced intestinal inflammation in mice via promoting M2 macrophage polarization. Pharmaceuticals (Basel). 2024;17(8):1023. doi:10.3390/ph17081023
CrossRef - Omasa T, Sawamoto A, Nakajima M, Okuyama S. Anti-inflammatory and neurotrophic factor production effects of 3,5,6,7,8,3′,4′-heptamethoxyflavone in the hippocampus of lipopolysaccharide-induced inflammation model mice. Molecules. 2024;29(23):5559. doi:10.3390/molecules29235559
CrossRef
Abbreviations
AA, ascorbic acid; COX, cyclooxygenase; ELISA, enzyme-linked immunosorbent assay; IL, interleukin; i.p., intraperitoneal; LD50, median lethal dose; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor kappa B; NLRP3, NOD-like receptor family pyrin domain-containing 3; NSAIDs, non-steroidal anti-inflammatory drugs; SD, standard deviation; SOCS3, suppressor of cytokine signalling 3; STAT3, signal transducer and activator of transcription 3; TLR4, Toll-like receptor 4; TNF-α, tumour necrosis factor-alpha





